Published in Oncogene on January 22, 2004
DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol (2007) 2.47
p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A (2012) 1.71
A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res (2009) 1.26
Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci (2012) 1.15
Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. Curr Genomics (2009) 1.11
Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. Clin Cancer Res (2014) 0.98
Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells. Oncotarget (2014) 0.86
The epigenetics of adult (somatic) stem cells. Crit Rev Eukaryot Gene Expr (2008) 0.83
Combined treatment with low concentrations of decitabine and SAHA causes cell death in leukemic cell lines but not in normal peripheral blood lymphocytes. Biomed Res Int (2013) 0.82
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clin Epigenetics (2016) 0.77
p53 and DNA methylation suppress the TRAIN to cell death. Cell Cycle (2012) 0.76
The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA. Oncotarget (2017) 0.75
Alteration of the DNA methylation status of donor cells impairs the developmental competence of porcine cloned embryos. J Reprod Dev (2015) 0.75
DNA hypomethylation upregulates expression of the MGAT3 gene in HepG2 cells and leads to changes in N-glycosylation of secreted glycoproteins. Sci Rep (2016) 0.75
Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers. J Cancer Res Clin Oncol (2016) 0.75
Identification of Predictive DNA Methylation Biomarkers for Chemotherapy Response in Colorectal Cancer. Front Pharmacol (2017) 0.75
The cardiac glycoside convallatoxin inhibits the growth of colorectal cancer cells in a p53-independent manner. Mol Genet Metab Rep (2017) 0.75
5-aza-2',2'-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer. Pharmaceuticals (Basel) (2017) 0.75
Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46
The hallmarks of aging. Cell (2013) 14.29
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Cellular senescence in cancer and aging. Cell (2007) 9.04
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol (2003) 8.42
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature (2009) 7.96
The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature (2009) 7.39
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics (2011) 7.38
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci (2003) 6.24
Cancer epigenetics reaches mainstream oncology. Nat Med (2011) 5.83
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A (2008) 5.21
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07
Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell (2009) 4.59
DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol (2006) 4.38
A role for RNAi in the selective correction of DNA methylation defects. Science (2009) 4.30
The common biology of cancer and ageing. Nature (2007) 4.28
Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci U S A (2012) 4.26
"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J (2002) 4.17
Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol (2004) 4.15
Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet (2012) 4.04
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
Delayed ageing through damage protection by the Arf/p53 pathway. Nature (2007) 3.87
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
DNA methylation and cancer. Adv Genet (2010) 3.50
Epigenetics and aging: the targets and the marks. Trends Genet (2007) 3.44
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab (2006) 3.22
Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol (2009) 3.05
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun (2010) 2.97
Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology (2008) 2.91
Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87
Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell (2010) 2.86
The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer (2006) 2.85
Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell (2008) 2.85
A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell (2010) 2.78
Programmed cell senescence during mammalian embryonic development. Cell (2013) 2.78
A systematic profile of DNA methylation in human cancer cell lines. Cancer Res (2003) 2.75
DNA methylation: a profile of methods and applications. Biotechniques (2002) 2.74
The role of histone deacetylases (HDACs) in human cancer. Mol Oncol (2007) 2.72
The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell (2004) 2.65
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Notch signaling is essential for ventricular chamber development. Dev Cell (2007) 2.53
Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature (2006) 2.51
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet (2011) 2.47
Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature (2013) 2.47
Epigenetic regulation of Nanog expression by Ezh2 in pluripotent stem cells. Cell Cycle (2011) 2.45
A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol (2008) 2.43
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res (2003) 2.41
Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway. Cell Cycle (2010) 2.41
Allele-specific histone lysine methylation marks regulatory regions at imprinted mouse genes. EMBO J (2002) 2.40
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2002) 2.34
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33
Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol (2005) 2.27
p53: guardian of the genome and policeman of the oncogenes. Cell Cycle (2007) 2.23
Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J (2007) 2.21
Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J (2003) 2.21
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21
A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics (2009) 2.21
BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol (2010) 2.18
Cross-talk between aging and cancer: the epigenetic language. Ann N Y Acad Sci (2007) 2.17
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res (2006) 2.15
A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle (2011) 2.13
CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle (2007) 2.12
Cancer epigenomics: beyond genomics. Curr Opin Genet Dev (2012) 2.11
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst (2004) 2.08
SIRT1: recent lessons from mouse models. Nat Rev Cancer (2010) 2.07
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res (2003) 2.03
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood (2008) 1.97
Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res (2007) 1.97
miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle (2010) 1.95
Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet (2003) 1.93
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res (2004) 1.92
The role of epigenetics in aging and age-related diseases. Ageing Res Rev (2009) 1.89
The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res (2009) 1.87